Défis associés à la rétine médicale et au diabète

Mon statut pour la session

Quand:

3:45 PM, Dimanche 3 Juin 2018 (1 heure 30 minutes)

Où:

Metro Toronto Convention Centre (Édifice Sud) - Salle 803

Thème:

Rétine

OBJECTIFS D'APPRENTISSAGE
À la fin de la session, les participants pourront :

Évaluer la façon dont les constatations tomographiques et cliniques issues de techniques d’imagerie multimodales en DMA néovasculaire et rétinopathie diabétique peuvent influencer à terme l’issue de la vision.
Décrire la prévisibilité de la réponse de différentes cytokines intraoculaires à la thérapie anti VEGF dans l’œdème maculaire diabétique.

RÔLES CANMEDS: Expert médical, promoteur de la santé

Varun Chaudhary

Modérateur.rice

Peter Kertes

Modérateur.rice

Sous sessions

Introduction

3:45 PM - 3:50 PM | 5 minutes

Multifocal electroretinographic changes after cessation of plaquenil therapy for suspected toxicity

3:50 PM - 4:00 PM | 10 minutes

Authors: Beatrice Adamptey, Chris Rudnisky, Ian M. MacDonald Author Disclosure Block: B. Adamptey: None. C. Rudnisky: None. I.M. MacDonald: None. Abstract Body: Purpose: To describe multifocal electroretinogram (mfERG) changes among patients suspected to show hydroxychloroquine (Plaquenil) toxicity and their outcomes after discontinuation of Plaquenil therapy. Study Design: A retrospective case series of 14 patients followe...

Beatrice Adamptey MD

Participant.e

Canadian treat and extend analysis trial with ranibizumab in patients with neovascular AMD: CANTREAT study one year results

4:00 PM - 4:10 PM | 10 minutes

Authors: Peter Kertes, Tom Sheidow, Geoff Williams, Mark Greve, Ivan Galic, Emmanouil Rampakakis, Joanne Gavalakis, Andrea Scarino Author Disclosure Block: P. Kertes: Grant/research support; Novartis, Bayer. Major stock shareholder; Arctic Dx.. Membership on an advisory panel, standing committee or board of directors; Novartis, Bayer, Alcon. T. Sheidow: Membership on an advisory panel, standing committee or board of directors; Novartis, Bayer, Alcon. G. Williams: Membership ...

Peter Kertes

Participant.e

Prevalence of obstructive sleep apnea in patients with retinal vein occlusion

4:10 PM - 4:20 PM | 10 minutes

Authors: Michael H. Brent, Tina Felfeli, Efrem D. Mandelcorn, Colin Shapiro, Roy Alon Author Disclosure Block: M. Brent: Grant/research support; Novartis, Allergan, Bayer, Roche. Membership on an advisory panel, standing committee or board of directors; Novartis, Bayer, Allergan, Alcon. T. Felfeli: None. E. Mandelcorn: Employment/honoraria/consulting fees; Novartis, Bayer, Optos, Bausch & Lomb. C. Shapiro: None. R. Alon: None. Abstract Body: Pur...

Michael Brent MD

Participant.e

The association of aqueous cytokines with long-term response to intravitreal ranibizumab in diabetic macular edema

4:20 PM - 4:30 PM | 10 minutes

Authors: Tina Felfeli, Verena Juncal, Roxane J. Hillier, Elvis Ojaimi, David T. Wong, Michael Y. K. Mak, Alan R. Berger, Radha P. Kohly, Peter J. Kertes, Farzin Forooghian, Shelley R. Boyd, Filiberto Altomare, Louis R. Giavedoni, Rosane Nisenbaum, Rajeev H. Muni Author Disclosure Block: T. Felfeli: None. V. Juncal: None. R.J. Hillier: None. E. Ojaimi: None. D.T. Wong: None. M.Y.K. Mak: None. A.R. Berger: None. R.P. Kohly: None. P.J. Kertes: None. F. Forooghian: None. ...

Dr. Verena Juncal

Participant.e

Time to treatment - A tele-retinal referral system for wet age-related macular degeneration and diabetic macular edema